Guardant Health, Inc.

    Jurisdiction
    United States
    LEI
    254900M8C3E5VC8BR186
    ISIN
    US40131M1099 (GH)
    Sectors
    1. Healthcare
    2. Medical - Diagnostics & Research

    Scores

    InsiderPie Expert Score
    63 / 100
    Better than peer group:
    57 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Read full profile

    Fundamentals

    Net revenue
    €706.97M
    Gross margin
    62.8%
    EBIT
    -€392.99M
    EBIT margin
    -55.6%
    Net income
    -€352.97M
    Net margin
    -49.9%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €975.16M +37.9% -€269.67M -23.6%
    €1.22B +25.5% -€191.13M -29.1%
    €1.65B +35.0% -€67.76M -64.5%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Joyce Meghan V. N/A -100 $65.84 -$6.58K
    Kalia Kumud Chief Information Officer -2K $61.76 -$123.52K
    POTTER MYRTLE S N/A -26 $59.02 -$1.53K
    Tariq Musa N/A -116 $59.02 -$6.85K
    POTTER MYRTLE S N/A -26 $48.20 -$1.25K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    James Anderson 5.1M $215.60M -388K Sell
    Cathie Wood 1.4M $60.03M -31K Sell
    Peter Brown 617K $26.26M +113K Buy

    Earnings Calls

    Latest earnings call: May 8, 2024 (Q1 2024)

    Add to watchlist

    Notifications